Alto Neuroscience (ANRO) Reports Topline Results from a Phase 2b Trial of ALTO-100

Go back to Alto Neuroscience (ANRO) Reports Topline Results from a Phase 2b Trial of ALTO-100
(NYSE: ANRO) Delayed: 35.81 --0 (-0%)
Previous Close $35.81    52 Week High
Open $35.81    52 Week Low
Day High $35.81    P/E N/A 
Day Low $35.81    EPS
Volume 1,258